药物化学第21届国际学术研讨会。

Idrugs Pub Date : 2010-11-01

Danny Chan

{"title":"药物化学第21届国际学术研讨会。","authors":"Danny Chan","doi":"","DOIUrl":null,"url":null,"abstract":"The XXIst International Symposium on Medicinal Chemistry from the European Federation of Medicinal Chemistry (EFMC-ISMC), held in Brussels, included topics covering new therapeutic developments in the field of medicinal research. This conference report highlights selected presentations on therapies for neuropathic pain, cognitive disorders, cancer and infection. Investigational drugs discussed include the anticancer imidazole derivative IRC-083927 (Ipsen), the HCV protease inhibitor TMC-435 (Tibotec Pharmaceuticals) and the tuberculosis therapy bedaquiline (Tibotec Pharmaceuticals).","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"749-52"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Medicinal Chemistry - XXIst International Symposium.\",\"authors\":\"Danny Chan\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The XXIst International Symposium on Medicinal Chemistry from the European Federation of Medicinal Chemistry (EFMC-ISMC), held in Brussels, included topics covering new therapeutic developments in the field of medicinal research. This conference report highlights selected presentations on therapies for neuropathic pain, cognitive disorders, cancer and infection. Investigational drugs discussed include the anticancer imidazole derivative IRC-083927 (Ipsen), the HCV protease inhibitor TMC-435 (Tibotec Pharmaceuticals) and the tuberculosis therapy bedaquiline (Tibotec Pharmaceuticals).\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 11\",\"pages\":\"749-52\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

欧洲药物化学联合会(EFMC-ISMC)第21届国际药物化学研讨会在布鲁塞尔举行，主题涵盖了药物研究领域的新治疗发展。本会议报告重点介绍了神经性疼痛、认知障碍、癌症和感染的治疗方法。讨论的研究药物包括抗癌咪唑衍生物IRC-083927 (Ipsen)， HCV蛋白酶抑制剂TMC-435 (Tibotec Pharmaceuticals)和结核病治疗贝达喹啉(Tibotec Pharmaceuticals)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Medicinal Chemistry - XXIst International Symposium.

The XXIst International Symposium on Medicinal Chemistry from the European Federation of Medicinal Chemistry (EFMC-ISMC), held in Brussels, included topics covering new therapeutic developments in the field of medicinal research. This conference report highlights selected presentations on therapies for neuropathic pain, cognitive disorders, cancer and infection. Investigational drugs discussed include the anticancer imidazole derivative IRC-083927 (Ipsen), the HCV protease inhibitor TMC-435 (Tibotec Pharmaceuticals) and the tuberculosis therapy bedaquiline (Tibotec Pharmaceuticals).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊